ACIP Presentation Slides: June 22-23, 2022 Meeting

Note: These files are not yet 508

Slides will be added as they become available.

June 22, 2022

Welcome & Introductions

• Introduction
  Dr. G Lee
  Dr. M Wharton

Influenza Vaccine

• Introduction [5 pages]
  Dr. K Talbot
• Vaccine effectiveness update [13 pages]
  Dr. J Chung
• Influenza vaccination of older adults [64 pages]
  Dr. L Grohskopf
• Summary, work group considerations, and proposed 2022-23 recommendations [12 pages]
  Dr. L Grohskopf

Pneumococcal Vaccines

• Introduction [15 pages]
  Dr. K Poehling
• PCV15 Pediatric Clinical Development Program – Update [16 pages]
  Dr. N Banniettis
• Economic analysis and public health Impact of PCV15 use in children [15 pages]
  Dr. A Leidner
• Summary of WG interpretation on EtR [71 pages]
  Dr. M Kobayashi
• Proposed recommendations for PCV15 use in children [21 pages]
  Dr. M Kobayashi

Measles, Mumps, and Rubella (MMR) Vaccine

• Introduction [4 pages]
  Ms. L Bahta
• EtR and proposed recommendations [92 pages]
  Dr. E Krow-Lucal

Human Papillomavirus (HPV) Vaccine Informational Session

• Introduction [8 pages]
  Dr. L Markowitz
• National and state-level HPV vaccination coverage [19 pages]
  Dr. S Stokley
• Impact of the US HPV vaccination program on HPV-associated outcomes [15 pages]
  Dr. J Gargano
• One-dose HPV vaccination – overview of current evidence [33 pages]
  Dr. L Markowitz

June 23, 2022

Welcome & Introductions

• Introduction
  Dr. G Lee
  Dr. M Wharton

Agency Updates

Coronavirus Disease 2019 (COVID-19) Vaccines

• Introduction [12 slides]
  Dr. M Daley
  
• Burden, prevalence and trends of long-term sequelae of SARS-CoV-2 [19 pages]
  Dr. M Briggs-Hagen
• Updates on safety of COVID-19 vaccines in children and adolescents [41 pages]
  Dr. T Shimabukuro
• VaST assessment [15 pages]
  Dr. K Talbot
• Moderna COVID-19 vaccine (mRNA-1273): Safety, immunogenicity and efficacy in children and adolescents ages 6-17 years [34 pages]
  Dr. R Das
• Evidence to Recommendation Framework: Moderna COVID-19 vaccine in children and adolescents ages 6-17 years [111 pages]
  Dr. S Oliver
• Clinical Considerations update [26 pages]
  Dr. E Hall

Meningococcal Vaccines

• Session postponed

Respiratory Syncytial Virus (RSV) Vaccine

• Introduction [9 pages]
  Dr. C Kotton
• RSV virion & vaccine products [11 pages]
  Dr. N Thornburg
• Epidemiology of RSV in children [19 pages]
  Dr. M McMorrow 
• Epidemiology of RSV in adults [23 pages]
  Dr. F Havers
• Safety and efficacy of Nirsevimab in infants [27 pages]
  Dr. C Felter

Chikungunya Vaccines

• Session postponed

Monkeypox Informational Session

• Situational update [16 pages]
  Dr. A Rao
• Medical countermeasures [19 pages]
  Dr. B Peterson